share_log

Aurora Cannabis | 6-K: Aurora Receives Expanded Cultivation and Unique Research Licenses for German Facility

Aurora Cannabis | 6-K: Aurora Receives Expanded Cultivation and Unique Research Licenses for German Facility

极光大麻 | 6-K:极光大麻获得德国工厂扩大种植和独特研究许可
美股SEC公告 ·  2024/07/27 02:21

Moomoo AI 已提取核心信息

Aurora Cannabis has obtained two expanded licenses from Germany's Federal Institute for Drugs and Medical Devices (BfArM) under the new Medical Cannabis Act. The licenses grant continued domestic cultivation rights, permission to cultivate an additional product, and a dedicated R&D license for testing up to seven novel cultivars at their EU GMP facility in Leuna.The company's Leuna facility has been producing approximately 1,000 kg of medical cannabis flower annually since 2021 under a tender agreement with BfArM. The enhanced licenses will enable Aurora to expand its portfolio and strengthen its position in Germany's growing medical cannabis market through local production and research capabilities.Michael Simon, President of Aurora Europe, emphasized the company's commitment to quality and compliance, which led to these license approvals. The development aligns with Germany's regulatory reforms and is expected to improve patient access to medical cannabis while potentially influencing broader acceptance across Europe.
Aurora Cannabis has obtained two expanded licenses from Germany's Federal Institute for Drugs and Medical Devices (BfArM) under the new Medical Cannabis Act. The licenses grant continued domestic cultivation rights, permission to cultivate an additional product, and a dedicated R&D license for testing up to seven novel cultivars at their EU GMP facility in Leuna.The company's Leuna facility has been producing approximately 1,000 kg of medical cannabis flower annually since 2021 under a tender agreement with BfArM. The enhanced licenses will enable Aurora to expand its portfolio and strengthen its position in Germany's growing medical cannabis market through local production and research capabilities.Michael Simon, President of Aurora Europe, emphasized the company's commitment to quality and compliance, which led to these license approvals. The development aligns with Germany's regulatory reforms and is expected to improve patient access to medical cannabis while potentially influencing broader acceptance across Europe.
极光大麻已从德国联邦药品和医疗设备机构(BfArM)获得两项扩展许可证,依据新的医疗大麻法案。这些许可证授予公司继续在国内种植的权利,允许种植额外产品,并为在其莱乌纳的欧盟GMP设施中测试多达七种新研发品种提供专用研发许可证。自2021年以来,该公司在与BfArm的招标协议下,莱乌纳设施每年生产约1000公斤医疗大麻花。增强许可证将使极光能够扩大其产品组合,并通过本地生产和研究能力增强其在德国不断增长的医疗大麻市场中的地位。极光欧洲总裁迈克尔·西蒙强调了公司对质量和合规性的承诺,这促成了这些许可证的批准。此发展符合德国的监管改革,预计将改善患者获取医疗大麻的途径,同时可能影响欧洲地区更广泛的接受度。
极光大麻已从德国联邦药品和医疗设备机构(BfArM)获得两项扩展许可证,依据新的医疗大麻法案。这些许可证授予公司继续在国内种植的权利,允许种植额外产品,并为在其莱乌纳的欧盟GMP设施中测试多达七种新研发品种提供专用研发许可证。自2021年以来,该公司在与BfArm的招标协议下,莱乌纳设施每年生产约1000公斤医疗大麻花。增强许可证将使极光能够扩大其产品组合,并通过本地生产和研究能力增强其在德国不断增长的医疗大麻市场中的地位。极光欧洲总裁迈克尔·西蒙强调了公司对质量和合规性的承诺,这促成了这些许可证的批准。此发展符合德国的监管改革,预计将改善患者获取医疗大麻的途径,同时可能影响欧洲地区更广泛的接受度。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息